1
|
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 2017; 35:547-573. [PMID: 28025748 DOI: 10.1007/s10555-016-9653-x] [Citation(s) in RCA: 153] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and "Triple-negative" (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.
Collapse
Affiliation(s)
- Lacey E Dobrolecki
- The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston,, TX, 77030, USA
| | | | - Denis G Alferez
- Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester, M21 4QL, UK
| | - Samuel Aparicio
- Department of Pathology and Laboratory Medicine, BC Cancer Agency, 675 W10th Avenue, Vancouver, V6R 3A6, Canada
| | - Fariba Behbod
- Department of Pathology, University of Kansas Medical Center
- 3901 Rainbow Blvd, WHE 1005B, Kansas City, KS, 66160, USA
| | - Mohamed Bentires-Alj
- Department of Biomedicine, University of Basel, University Hospital Basel, Lab 306, Hebelstrasse 20, CH-4031, Basel, Switzerland
| | - Cathrin Brisken
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), ISREC-Swiss Institute for Experimental Cancer Research, SV2.832 Station 19, 1015, Lausanne, Switzerland
| | - Carol J Bult
- The Jackson Laboratory, Bar Harbor, ME, 04609, USA
| | - Shirong Cai
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Robert B Clarke
- Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester, M21 4QL, UK
| | - Heidi Dowst
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Matthew J Ellis
- The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston,, TX, 77030, USA
| | - Eva Gonzalez-Suarez
- Cancer Epigenetics and Biology Program, PEBC, Bellvitge Institute for Biomedical Research, IDIBELL, Av. Gran Via de L'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Richard D Iggo
- INSERM U1218, Bergonié Cancer Institute, 229 cours de l'Argonne, 33076, Bordeaux, France
| | - Peter Kabos
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA
| | - Shunqiang Li
- Department of Internal Medicine, Washington University, St. Louis, MO, 63130, USA
| | - Geoffrey J Lindeman
- Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.,Department of Medicine, The University of Melbourne, Parkville, VIC, 3010, Australia.,Familial Cancer Centre, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Grattan St, Parkville, VIC, 3050, Australia
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, 26, rue d'Ulm, 75005, Paris, France
| | - Aaron McCoy
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Funda Meric-Bernstam
- Departments of Investigational Cancer Therapeutics and Breast Surgical Oncology, UT M. D. Anderson Cancer Center, Houston, TX, 77030, USA
| | - Helen Piwnica-Worms
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Marie-France Poupon
- Founder and Scientific Advisor, XenTech SA, Genopole, 4 rue Pierre Fontaine, 91000, Evry, France
| | - Jorge Reis-Filho
- Director of Experimental Pathology, Department of Pathology, Affiliate Member, Human Oncology and Pathogenesis Program, and Center for Computational Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Carol A Sartorius
- Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA
| | - Valentina Scabia
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), ISREC-Swiss Institute for Experimental Cancer Research, SV2.832 Station 19, 1015, Lausanne, Switzerland
| | - George Sflomos
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), ISREC-Swiss Institute for Experimental Cancer Research, SV2.832 Station 19, 1015, Lausanne, Switzerland
| | - Yizheng Tu
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - François Vaillant
- Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, VIC, 3010, Australia
| | - Jane E Visvader
- Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.,Department of Medical Biology, University of Melbourne, Parkville, VIC, 3010, Australia
| | - Alana Welm
- Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT, 84112, USA
| | - Max S Wicha
- Madeline and Sidney Forbes Professor of Oncology, Director, Forbes Institute for Cancer Discovery, NCRC 26-335S, SPC 2800 2800 Plymouth Rd, Ann Arbor, MI, 48109-2800, USA
| | - Michael T Lewis
- The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston,, TX, 77030, USA.
| |
Collapse
|
2
|
Wiese KE, Amante RJ, Vivanco MDM, Bentires-Alj M, Iggo RD. The ninth ENBDC Weggis meeting: growth and in-depth characterisation of normal and neoplastic breast cells. Breast Cancer Res 2017; 19:96. [PMID: 28830566 PMCID: PMC5568390 DOI: 10.1186/s13058-017-0891-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Mammary gland biologists gathered for the ninth annual workshop of the European Network for Breast Development and Cancer (ENBDC) at Weggis on the shores of Lake Lucerne in March 2017. The main themes were oestrogen receptor alpha signalling, new techniques for mammary cell culture, CRISPR screening and proteogenomics.
Collapse
Affiliation(s)
- Katrin E Wiese
- Section of Molecular Cytology and Van Leeuwenhoek Centre for Advanced Microscopy, Swammerdam Institute for Life Sciences, University of Amsterdam, 1098 XH, Amsterdam, The Netherlands
| | - Romain J Amante
- Department of Biomedicine, University of Basel, University Hospital Basel, Hebelstrasse 20, CH-4031, Basel, Switzerland
| | | | - Mohamed Bentires-Alj
- Department of Biomedicine, University of Basel, University Hospital Basel, Hebelstrasse 20, CH-4031, Basel, Switzerland
| | - Richard D Iggo
- INSERM U1218, Institut Bergonie, University of Bordeaux, 229 cours de l'Argonne, 33076, Bordeaux, France.
| |
Collapse
|
3
|
Lim JH, Latysheva NS, Iggo RD, Barker D. Cluster Analysis of p53 Binding Site Sequences Reveals Subsets with Different Functions. Cancer Inform 2016; 15:199-209. [PMID: 27812278 PMCID: PMC5081245 DOI: 10.4137/cin.s39968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 08/31/2016] [Accepted: 09/09/2016] [Indexed: 11/05/2022] Open
Abstract
p53 is an important regulator of cell cycle arrest, senescence, apoptosis and metabolism, and is frequently mutated in tumors. It functions as a tetramer, where each component dimer binds to a decameric DNA region known as a response element. We identify p53 binding site subtypes and examine the functional and evolutionary properties of these subtypes. We start with over 1700 known binding sites and, with no prior labeling, identify two sets of response elements by unsupervised clustering. When combined, they give rise to three types of p53 binding sites. We find that probabilistic and alignment-based assessments of cross-species conservation show no strong evidence of differential conservation between types of binding sites. In contrast, functional analysis of the genes most proximal to the binding sites provides strong bioinformatic evidence of functional differentiation between the three types of binding sites. Our results are consistent with recent structural data identifying two conformations of the L1 loop in the DNA binding domain, suggesting that they reflect biologically meaningful groups imposed by the p53 protein structure.
Collapse
Affiliation(s)
- Ji-Hyun Lim
- School of Biology, University of St Andrews, St Andrews, UK
- School of Medicine, University of St Andrews, St Andrews, UK
- Current address: Alacris Theranostics GmbH, Berlin, Germany
| | - Natasha S. Latysheva
- School of Biology, University of St Andrews, St Andrews, UK
- Current address: MRC Laboratory of Molecular Biology, Cambridge, UK
| | - Richard D. Iggo
- School of Medicine, University of St Andrews, St Andrews, UK
- INSERM Unit U1218, University of Bordeaux, Institut Bergonie, Bordeaux, France
| | - Daniel Barker
- School of Biology, University of St Andrews, St Andrews, UK
- Current address: Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD. Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. Breast Cancer Res 2015; 17:126. [PMID: 26376855 PMCID: PMC4573692 DOI: 10.1186/s13058-015-0612-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 07/08/2015] [Indexed: 11/10/2022] Open
Abstract
Due to a typesetting error, the labelling was changed and the figures in this article [1] were presented in the order 2, 4, 10, 6, 1, 3, 5, 7, 8, 9, 11, 12, 13, 14 and the supplementary figure links were inverted. The revised version has the figures in the correct order.
Collapse
Affiliation(s)
- Stephanie Verbeke
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - Elodie Richard
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - Elodie Monceau
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - Xenia Schmidt
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.,School of Medicine, University of St Andrews, Medical and Biological Sciences Building, North Haugh, St Andrews, KY16 9TF, UK
| | - Benoit Rousseau
- Animalerie A2, University of Bordeaux, 146 rue Léo Saignat, Bordeaux, 33076, France
| | - Valerie Velasco
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.,Pathology Department, Bergonié Cancer Institute, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - David Bernard
- INSERM U1052, Centre Leon Berard, University of Lyon, 28 rue Laennec, Lyon, 69008, France
| | - Herve Bonnefoi
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - Gaetan MacGrogan
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.,Pathology Department, Bergonié Cancer Institute, 229 cours de l'Argonne, Bordeaux, 33076, France
| | - Richard D Iggo
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France. .,School of Medicine, University of St Andrews, Medical and Biological Sciences Building, North Haugh, St Andrews, KY16 9TF, UK.
| |
Collapse
|
5
|
Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. Breast Cancer Res 2014; 16:504. [PMID: 25527189 PMCID: PMC4407301 DOI: 10.1186/s13058-014-0504-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 12/11/2014] [Indexed: 01/09/2023] Open
Abstract
Introduction The cell of origin for estrogen receptor α (ERα) positive breast cancer is
probably a luminal stem cell in the terminal duct lobular units. To model these
cells we have used the murine myoepithelial layer in the mouse mammary ducts as a
scaffold upon which to build a human luminal layer. To prevent squamous
metaplasia, a common artifact in genetically engineered breast cancer models, we
sought to limit activation of the epidermal growth factor receptor (EGFR) during
in vitro cell culture before grafting the
cells. Methods Human reduction mammoplasty cells were grown in
vitro in WIT medium. Epidermal growth factor (EGF) in the medium was
replaced with amphiregulin and neuregulin to decrease activation of EGFR and
increase activation of EGFR homologs 3 and 4 (ERBB3 and ERBB4). Lentiviral vectors
were used to express oncogenic transgenes and fluorescent proteins. Human mammary
epithelial cells were mixed with irradiated mouse fibroblasts and matrigel, then
injected through the nipple into the mammary ducts of immunodeficient mice.
Engrafted cells were visualized by stereomicroscopy for fluorescent proteins and
characterized by histology and immunohistochemistry. Results Growth of normal mammary epithelial cells in conditions favoring ERBB3/4
signaling prevented squamous metaplasia in
vitro. Normal human cells were quickly lost after intraductal
injection but cells infected with lentiviruses expressing CCND1, MYC, TERT, BMI1 and a
short hairpin RNA targeting TP53 were able to
engraft and progressively replace the luminal layer in the mouse mammary ducts,
resulting in the formation of an extensive network of humanized ducts. Despite
expressing multiple oncogenes, the human cells formed a morphologically normal
luminal layer. Expression of a single additional oncogene, PIK3CA-H1047R, converted the
cells into invasive cancer cells. The resulting tumors were ERα+, Ki67+ luminal B
adenocarcinomas that were resistant to treatment with fulvestrant. Conclusions Injection of preneoplastic human mammary epithelial cells into the mammary
ducts of immunodeficient mice leads to replacement of the murine luminal layer
with morphologically normal human cells. Genetic manipulation of the injected
cells makes it possible to study defined steps in the transformation of human
mammary epithelial cells in a more physiological environment than has hitherto
been possible. Electronic supplementary material The online version of this article (doi:10.1186/s13058-014-0504-9) contains supplementary material, which is available to authorized
users.
Collapse
Affiliation(s)
- Stephanie Verbeke
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.
| | - Elodie Richard
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.
| | - Elodie Monceau
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.
| | - Xenia Schmidt
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France. .,School of Medicine, University of St Andrews, Medical and Biological Sciences Building, North Haugh, St Andrews, KY16 9TF, UK.
| | - Benoit Rousseau
- Animalerie A2, University of Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France.
| | - Valerie Velasco
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France. .,Pathology Department, Bergonié Cancer Institute, 229 cours de l'Argonne, 33076, Bordeaux, France.
| | - David Bernard
- INSERM U1052, Centre Leon Berard, University of Lyon, 28 rue Laennec, 69008, Lyon, France.
| | - Herve Bonnefoi
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France.
| | - Gaetan MacGrogan
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France. .,Pathology Department, Bergonié Cancer Institute, 229 cours de l'Argonne, 33076, Bordeaux, France.
| | - Richard D Iggo
- INSERM U916, Bergonié Cancer Institute, University of Bordeaux, 229 cours de l'Argonne, Bordeaux, 33076, France. .,School of Medicine, University of St Andrews, Medical and Biological Sciences Building, North Haugh, St Andrews, KY16 9TF, UK.
| |
Collapse
|
6
|
Iggo RD, Wood HM, Rabbitts P, Quenel-Tueux N, Mauriac L, MacGrogan G, Bonnefoi H. Abstract PD3-3: Next generation sequencing shows clonal selection after treatment with anastrozole or fulvestrant in a randomized trial of postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd3-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Unlike chemotherapy, endocrine therapy is not clastogenic or mutagenic, so genetic changes arising during treatment are unlikely to be secondary events provoked by iatrogenic DNA damage. Endocrine therapy for breast cancer is thus a clean setting in which to explore the evolution of tumour genomes under treatment, and the changes seen are likely to be biologically meaningful. To identify such changes we have analysed pre and post treatment biopsies from a clinical trial that compared two endocrine therapies.
Patients and methods: DNA was extracted from pre and post treatment samples from 20 patients enrolled in the HORGEN trial. Postmenopausal patients with large operable or locally-advanced hormone-receptor-positive breast cancer were randomly assigned to receive either neoadjuvant anastrozole or fulvestrant for 6 months in this multicenter randomized phase II study. Low depth next generation sequencing was used to generate DNA copy number profiles for each sample.
Results: The copy number profiles were similar before and after treatment in 10 cases. In three cases new amplicons appeared. In one case the amplicon contained the ESR1 gene, in another the FOXA1 gene, and in the third the NCOA3 gene. In the remaining seven cases where the profiles changed after treatment, the differences affected whole chromosomal arms. In six of these cases the profiles became simpler, indicating that clones with gains and losses of chromosomal arms had been counterselected by the treatment.
Conclusions: Differences between the pre and post treatment biopsies were surprisingly frequent and informative. Genes directly implicated in estrogen signalling were amplified in three cases. This suggests that specific amplicons confer resistance to endocrine therapy. From a clinical perspective, their appearance in a post treatment biopsy probably indicates that the treatment should be changed. A possible explanation for the chromosomal arm changes after treatment, a phenomenon we have dubbed the “wandering arms” phenotype, is that endocrine therapy deprives tumour cells of signals that are necessary for the survival of clones with copy number changes affecting whole chromosomal arms.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD3-3.
Collapse
Affiliation(s)
- RD Iggo
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - HM Wood
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - P Rabbitts
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - N Quenel-Tueux
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - L Mauriac
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - G MacGrogan
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | - H Bonnefoi
- INSERM U916, Univ. Bordeaux, Institut Bergonié, Bordeaux, France; Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
| | | |
Collapse
|
7
|
Abstract
Genome-wide prediction of transcription factor binding sites is notoriously difficult. We have developed and applied a logistic regression approach for prediction of binding sites for the p53 transcription factor that incorporates sequence information and chromatin modification data. We tested this by comparison of predicted sites with known binding sites defined by chromatin immunoprecipitation (ChIP), by the location of predictions relative to genes, by the function of nearby genes and by analysis of gene expression data after p53 activation. We compared the predictions made by our novel model with predictions based only on matches to a sequence position weight matrix (PWM). In whole genome assays, the fraction of known sites identified by the two models was similar, suggesting that there was little to be gained from including chromatin modification data. In contrast, there were highly significant and biologically relevant differences between the two models in the location of the predicted binding sites relative to genes, in the function of nearby genes and in the responsiveness of nearby genes to p53 activation. We propose that these contradictory results can be explained by PWM and ChIP data reflecting primarily biophysical properties of protein–DNA interactions, whereas chromatin modification data capture biologically important functional information.
Collapse
Affiliation(s)
- Ji-Hyun Lim
- Sir Harold Mitchell Building, School of Biology, University of St Andrews, St Andrews, Fife, KY16 9TH, UK
| | | | | |
Collapse
|
8
|
Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Retraction—validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2011; 12:116. [DOI: 10.1016/s1470-2045(11)70011-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Schmidt X, Duss S, Iggo RD. Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells. Breast Cancer Res 2008. [PMCID: PMC3300726 DOI: 10.1186/bcr1907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
Funston GM, Kallioinen SE, de Felipe P, Ryan MD, Iggo RD. Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J Gen Virol 2008; 89:389-396. [PMID: 18198369 DOI: 10.1099/vir.0.83444-0] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Insertion of picornaviral 2A sequences into mRNAs causes ribosomes to skip formation of a peptide bond at the junction of the 2A and downstream sequences, leading to the production of two proteins from a single open reading frame. Adenoviral protein IX is a minor capsid protein that has been used to display foreign peptides on the surface of the capsid. We have used 2A sequences from the foot-and-mouth disease virus (FMDV) and porcine teschovirus 1 (PTV-1) to express protein IX (pIX) and green fluorescent protein (GFP) from pIX-2A-GFP fusion genes in an oncolytic virus derived from human adenovirus 5. GFP was efficiently expressed by constructs containing either 2A sequence. Peptide bond skipping was more efficient with the 58 aa FMDV sequence than with the 22 aa PTV-1 2A sequence, but the virus with the FMDV 2A sequence showed a reduction in plaque size, cytopathic effect, viral burst size and capsid stability. We conclude that ribosome skipping induced by 2A sequences is an effective strategy to express heterologous genes in adenoviruses; however, careful selection or optimization of the 2A sequence may be required if protein IX is used as the fusion partner.
Collapse
Affiliation(s)
- Garth M Funston
- School of Medicine, Biomolecular Sciences Building, University of St Andrews, St Andrews KY16 9ST, UK
| | - Susanna E Kallioinen
- School of Medicine, Biomolecular Sciences Building, University of St Andrews, St Andrews KY16 9ST, UK
| | - Pablo de Felipe
- School of Medicine, Biomolecular Sciences Building, University of St Andrews, St Andrews KY16 9ST, UK
| | - Martin D Ryan
- School of Biology, Biomolecular Sciences Building, University of St Andrews, St Andrews KY16 9ST, UK
| | - Richard D Iggo
- School of Medicine, Biomolecular Sciences Building, University of St Andrews, St Andrews KY16 9ST, UK
| |
Collapse
|
11
|
Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8:1071-1078. [PMID: 18024211 DOI: 10.1016/s1470-2045(07)70345-5] [Citation(s) in RCA: 145] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial. METHODS This trial compares a non-taxane regimen (fluorouracil, epirubicin, and cyclophosphamide [FEC] for six cycles) with a taxane regimen (docetaxel for three cycles followed by epirubicin plus docetaxel [TET] for three cycles) in women with oestrogen-receptor-negative breast cancer. The primary endpoint of the study is the difference in progression-free survival based on TP53 status and will be reported later. Predicting response with gene signatures was a planned secondary endpoint of the trial and is reported here. Pathological complete response, defined as complete disappearance of the tumour with no more than a few scattered tumour cells detected by the pathologist in the resection specimen, was used to assess chemosensitivity. RNA was prepared from sections of frozen biopsies taken at diagnosis and hybridised to Affymetrix X3P microarrays. In-vitro single-agent drug sensitivity signatures were combined to obtain FEC and TET regimen-specific signatures. This study is registered on the clinical trials site of the US National Cancer Institute website http://www.clinicaltrials.gov/ct/show/NCT00017095. FINDINGS Of 212 patients with oestrogen-receptor-negative tumours assessed, 87 patients were excluded. 125 oestrogen-receptor-negative tumours (55 that showed pathological complete responses) were tested: 66 in the FEC group (28 that showed pathological complete responses) and 59 in the TET group (27 that showed pathological complete responses). The regimen-specific signatures significantly predicted pathological complete response in patients treated with the appropriate regimen (p<0.0001). The FEC predictor had a sensitivity of 96% (27 of 28 patients [95% CI 82-99]), specificity of 66% (25 of 38 patients [50-79]), positive predictive value (PPV) of 68% (27 of 40 patients [52-80]), and negative predictive value (NPV) of 96% (25 of 26 patients [81-99]). The TET predictor had a sensitivity of 93% (25 of 27 patients [77-98]), specificity 69% (22 of 32 patients [51-82]), PPV of 71% (25 of 35 patients [55-84]), and NPV of 92% (22 of 24 patients [74-98]). Analysis of tumour size, grade, nodal status, age, and regimen-specific signatures showed that the genomic signatures were the only independent variables predicting pathological complete response at p<0.01. Selection of patients with these signatures would increase the proportion of patients with pathological complete responses from 44% to around 70% in the patients studied here. INTERPRETATION We have validated the use of regimen-specific drug sensitivity signatures in the context of a multicentre randomised trial. The high NPV of both signatures may allow early selection of patients with breast cancer who should be considered for trials with new drugs.
Collapse
Affiliation(s)
- Hervé Bonnefoi
- Geneva University Hospital, Geneva, Switzerland; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland.
| | - Anil Potti
- Duke Institute for Genome Sciences and Policy, and Duke University Medical Center, Durham, NC, USA
| | - Mauro Delorenzi
- Swiss Institute for Experimental Cancer Research (ISREC), National Centre of Competence in Research (NCCR), Epalinges, Switzerland; Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | - Pierre Farmer
- Swiss Institute for Experimental Cancer Research (ISREC), National Centre of Competence in Research (NCCR), Epalinges, Switzerland; Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland
| | - Sylvie André
- Swiss Institute for Experimental Cancer Research (ISREC), National Centre of Competence in Research (NCCR), Epalinges, Switzerland
| | - Chaitanya R Acharya
- Duke Institute for Genome Sciences and Policy, and Duke University Medical Center, Durham, NC, USA
| | - Sayan Mukherjee
- Duke Institute for Genome Sciences and Policy, and Duke University Medical Center, Durham, NC, USA
| | - David Cameron
- Anglo-Celtic Cooperative Oncology Group (ACCOG), Edinburgh University, Edinburgh, UK
| | - Jonas Bergh
- Swedish Breast Cancer Group (SweBCG), Karolinska Institute and Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden
| | - Joseph R Nevins
- Duke Institute for Genome Sciences and Policy, and Duke University Medical Center, Durham, NC, USA
| | - Richard D Iggo
- Swiss Institute for Experimental Cancer Research (ISREC), National Centre of Competence in Research (NCCR), Epalinges, Switzerland; University of St Andrews, Scotland, UK
| |
Collapse
|
12
|
Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD. An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. Breast Cancer Res 2007; 9:R38. [PMID: 17573968 PMCID: PMC1929103 DOI: 10.1186/bcr1734] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2007] [Revised: 05/29/2007] [Accepted: 06/15/2007] [Indexed: 11/30/2022] Open
Abstract
Introduction About 70% of breast cancers express oestrogen receptor α (ESR1/ERα) and are oestrogen-dependent for growth. In contrast with the highly proliferative nature of ERα-positive tumour cells, ERα-positive cells in normal breast tissue rarely proliferate. Because ERα expression is rapidly lost when normal human mammary epithelial cells (HMECs) are grown in vitro, breast cancer models derived from HMECs are ERα-negative. Currently only tumour cell lines are available to model ERα-positive disease. To create an ERα-positive breast cancer model, we have forced normal HMECs derived from reduction mammoplasty tissue to express ERα in combination with other relevant breast cancer genes. Methods Candidate genes were selected based on breast cancer microarray data and cloned into lentiviral vectors. Primary HMECs prepared from reduction mammoplasty tissue were infected with lentiviral particles. Infected HMECs were characterised by Western blotting, immunofluorescence microscopy, microarray analysis, growth curves, karyotyping and SNP chip analysis. The tumorigenicity of the modified HMECs was tested after orthotopic injection into the inguinal mammary glands of NOD/SCID mice. Cells were marked with a fluorescent protein to allow visualisation in the fat pad. The growth of the graft was analysed by fluorescence microscopy of the mammary glands and pathological analysis of stained tissue sections. Oestrogen dependence of tumour growth was assessed by treatment with the oestrogen antagonist fulvestrant. Results Microarray analysis of ERα-positive tumours reveals that they commonly overexpress the Polycomb-group gene BMI1. Lentiviral transduction with ERα, BMI1, TERT and MYC allows primary HMECs to be expanded in vitro in an oestrogen-dependent manner. Orthotopic xenografting of these cells into the mammary glands of NOD/SCID mice results in the formation of ERα-positive tumours that metastasise to multiple organs. The cells remain wild type for TP53, diploid and genetically stable. In vivo tumour growth and in vitro proliferation of cells explanted from tumours are dependent on oestrogen. Conclusion We have created a genetically defined model of ERα-positive human breast cancer based on normal HMECs that has the potential to model human oestrogen-dependent breast cancer in a mouse and enables the study of mechanisms involved in tumorigenesis and metastasis.
Collapse
Affiliation(s)
- Stephan Duss
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
| | - Sylvie André
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- St Andrews University Medical School, Bute Medical Building, St Andrews, KY16 9TS, UK
| | - Anne-Laure Nicoulaz
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
| | - Maryse Fiche
- Lausanne University Hospital, CHUV, CH-1011 Lausanne, Switzerland
| | - Hervé Bonnefoi
- Geneva University Hospitals, 30 Boulevard de la Cluse, CH-1211 Geneva, Switzerland
| | - Cathrin Brisken
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
| | - Richard D Iggo
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
- St Andrews University Medical School, Bute Medical Building, St Andrews, KY16 9TS, UK
| |
Collapse
|
13
|
Fuerer C, Homicsko K, Lukashev AN, Pittet AL, Iggo RD. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells. BMC Cancer 2006; 6:236. [PMID: 17020613 PMCID: PMC1609183 DOI: 10.1186/1471-2407-6-236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Accepted: 10/04/2006] [Indexed: 12/20/2022] Open
Abstract
Background The Wnt signaling pathway is activated by mutations in the APC and β-catenin genes in many types of human cancer. β-catenin is stabilized by these mutations and activates transcription in part by acting as a bridge between Tcf/LEF proteins and the HD2 domain of the BCL9 coactivator. We have previously described oncolytic adenoviruses with binding sites for Tcf/LEF transcription factors inserted into the early viral promoters. These viruses replicate selectively in cells with activation of the Wnt pathway. To increase the activity of these viruses we have fused the viral transactivator E1A to the BCL9 HD2 domain. Methods Luciferase assays, co-immunoprecipitation and Western blotting, immunofluorescent cell staining and cytopathic effect assays were used to characterize the E1A-HD2 fusion protein and virus in vitro. Growth curves of subcutaneous SW620 colon cancer xenografts were used to characterize the virus in vivo. Results The E1A-HD2 fusion protein binds to β-catenin in vivo and activates a Tcf-regulated luciferase reporter better than wild-type E1A in cells with activated Wnt signaling. Expression of the E1A-HD2 protein promotes nuclear import of β-catenin, mediated by the strong nuclear localization signal in E1A. Tcf-regulated viruses expressing the fusion protein show increased expression of viral proteins and a five-fold increase in cytopathic effect (CPE) in colorectal cancer cell lines. There was no change in viral protein expression or CPE in HeLa cells, indicating that E1A-HD2 viruses retain selectivity for cells with activation of the Wnt signaling pathway. Despite increasing the cytopathic effect of the virus in vitro, fusion of the HD2 domain to E1A did not increase the burst size of the virus in vitro or the anti-tumor effect of the virus in an SW620 xenograft model in vivo. Conclusion Despite an increase in the nuclear pool of β-catenin, the effects on viral activity in colon cancer cells were small, suggesting that factors acting downstream of β-catenin are limiting for viral replication and toxicity in these cells. The approach of fusing E1A to a protein domain implicated in oncogenic signaling could be used to selectively increase the activity of oncolytic viruses targeting several other pathways defective in cancer.
Collapse
Affiliation(s)
- Christophe Fuerer
- NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | - Krisztian Homicsko
- NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | - Alexander N Lukashev
- NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | - Anne-Laure Pittet
- NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | - Richard D Iggo
- NCCR Molecular Oncology Programme, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
- Current address: Bute Medical School, University of St Andrews, Fife KY16 9TS, Scotland, UK
| |
Collapse
|
14
|
Abstract
Selectively replicating adenoviruses have the potential to cure cancer but have shown little efficacy in clinical trials. We have tested the ability of the mTOR kinase inhibitor RAD001 (everolimus) to enhance the response of xenografts to an oncolytic adenovirus. The virus has Tcf sites inserted in the early viral promoters and replicates selectively in cells with activation of the Wnt signaling pathway. To enhance tumor cell infection, an integrin targeting peptide (CDCRGDCFC) was inserted into the fiber gene of the virus. RAD001 combines three useful properties: it inhibits tumor cell growth directly, blocks angiogenesis, and suppresses the immune response. RAD001 does not block viral protein expression, DNA replication, or cytopathic effect in tumor cells in vitro. After 6 weeks of daily RAD001 treatment, ongoing viral DNA replication could be detected in tumor xenografts, showing that RAD001 does not inhibit virus replication in vivo. I.v. injection of virus alone produced a small delay in xenograft growth, whereas combination therapy substantially prolonged the survival of the mice. We suggest that collapsing the tumor vasculature after the initial infection traps the virus and facilitates local spread within the tumor. Unlike conventional drugs, which require continued access to the tumor through the vascular system, oncolytic viruses are in principle less sensitive to late reductions in perfusion because they are produced locally within the tumor.
Collapse
Affiliation(s)
- Krisztian Homicsko
- National Center of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | | | |
Collapse
|
15
|
Abstract
We have used chromatin immunoprecipitation (ChIP) to measure p53-dependent histone acetylation at the p21, MDM2, and PUMA promoters. The pattern of histone acetylation was different at each promoter. H3 and H4 acetylation increased at both the p21 and PUMA promoters in response to p53 activation, whereas there was only a minimal increase in H4 acetylation and no increase in H3 acetylation at the MDM2 promoter. The high p53 occupancy of the p21, MDM2 and PUMA promoters has been attributed to the presence of two p53 binding sites in these promoters, but mutation of the p53 binding sites in integrated p21 promoter constructs showed that the two sites in the p21 promoter do not cooperate to stabilize p53 binding. Despite 10-fold higher p53 binding to the proximal than the distal site in the p21 promoter, both sites showed similar patterns of H3 and H4 acetylation. Mutation of the binding sites showed that acetylation of the proximal, low-affinity site requires p53 binding to that site but not to the distal, high-affinity site. Since low-affinity p53 binding sites can confer strong acetylation, the DNA binding affinity in vitro is an unreliable guide to the likely importance of p53 in regulating candidate target genes in vivo.
Collapse
Affiliation(s)
- Matthias D Kaeser
- Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), ch. des Boveresses 155, 1066 Epalinges, Switzerland
| | | |
Collapse
|
16
|
Abstract
RNA interference is widely used to silence gene expression in mammalian cells. We recently reported that an shRNA expressed from the H1 promoter in a lentiviral vector could induce the expression of a large group of interferon-stimulated genes (ISGs). This response was unrelated to silencing of the gene targeted by the shRNA MORF4L1. In parallel, we constructed lentiviral vectors expressing shRNA from the U6 promoter and found that these too could induce expression of OAS1, a classic interferon target gene. The U6 vectors give a higher frequency of ISG induction than comparable lentiviral H1 vectors, suggesting that there might be a fundamental flaw in the vector design. We have characterized the U6 vectors in detail and report here that ISG induction is a consequence of the presence of an AA di-nucleotide near the transcription start site. A single nucleotide deletion in the siRNA sequence abolished OAS1 induction, suggesting that the mechanism underlying the response uses a sensor that can detect 19 bp RNA duplexes but not 14 bp duplexes. Adenoviral VA RNA I, which inhibits dsRNA-dependent protein kinase (PKR), was tested as a fusion partner to express shRNA on the grounds that it might prevent nonspecific off-target effects. Fusion of VA RNA I to a lamin shRNA was moderately effective in silencing lamin expression, but gave strong OAS1 induction by an shRNA that does not induce OAS1 when expressed from the U6 or H1 promoters. To avoid interferon induction by U6 vectors, we recommend preserving the wild-type sequence around the transcription start site, in particular a C/G sequence at positions -1/+1, and we describe a simple cloning strategy using the Gateway recombination system that facilitates this task.
Collapse
Affiliation(s)
- Stephanie Pebernard
- Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Ch. des Boveresses, 1066 Epalinges, Switzerland
| | | |
Collapse
|
17
|
Abstract
We have used a lentiviral vector to stably express p53 at a physiological level in p53 knockout HCT116 cells. Cells transduced with wild type p53 responded to genotoxic stress by stabilizing p53 and expressing p53 target genes. The reconstituted cells underwent G(1) arrest or apoptosis appropriately depending on the type of stress, albeit less efficiently than parental wild type cells. Compared with cells expressing exogenous wild type p53, the apoptotic response to 5-fluorouracil (5FU) was >50% reduced in cells expressing S15A or S20A mutant p53, and even more reduced by combined mutation of serines 6, 9, 15, 20, 33, and 37 (N6A). Among a panel of p53 target genes tested by quantitative PCR, the gene showing the largest defect in induction by 5FU was BBC3 (PUMA), which was induced 4-fold by wild type p53 and 2-fold by the N6A mutant. Mutation of N-terminal phosphorylation sites did not prevent p53 stabilization by doxorubicin or 5FU. MDM2 silencing by RNA interference activated p53 target gene expression in normal fibroblasts but not in HCT116 cells, and exogenous p53 could be stabilized in HCT116 knockout cells despite combined mutation of p53 phosphorylation sites and silencing of MDM2 expression. The MDM2 feedback loop is thus defective, and other mechanisms must exist to regulate p53 stability and function in this widely used tumor cell line.
Collapse
Affiliation(s)
- Matthias D Kaeser
- Oncogene Group, Swiss Institute for Experimental Cancer Research, Ch des Boveresses 155, 1066 Epalinges, Switzerland
| | | | | |
Collapse
|
18
|
Abstract
The wnt signaling pathway is constitutively activated in colon tumors by mutations in the adenomatous polyposis coli and beta-catenin genes. We have modified the minute virus of mice (MVM) P4 promoter to make it responsive to wnt signaling by inserting binding sites for the heterodimeric beta-catenin/Tcf transcription factor. In luciferase assays we can see up to 20-fold selectivity of Tcf mutant P4 promoters for cells with activated wnt signaling. Hybrid MVM/H-1 viruses containing Tcf mutant promoters were tested for NS1 expression, viral DNA replication, virus replication, and cytopathic effect on colon, lung, kidney, and cervical cancer cell lines. Activation of the wnt pathway by expression of Delta N-beta-catenin increased NS1 expression and viral burst size in 293T and H1299 lung cancer cells, showing that the Tcf mutant P4 promoter can respond to wnt signals in the context of the virus. Compared to the parental virus, the burst size of the Tcf mutant viruses was reduced at least 1,000-fold in H1299, 293T, NB324K, and HeLa cells, which have inactive wnt signaling pathways. The burst size and cytopathic effect of the Tcf viruses was near wild-type levels in SW480 and Isreco1 colon cancer cell lines, which have high Tcf activity. The high specificity of these viruses should permit the development of H-1 virus-based vectors which combine high safety and greater efficacy in cancer therapy.
Collapse
Affiliation(s)
- M Malerba
- Swiss Institute for Experimental Cancer Research (ISREC), CH-1066 Epalinges, Switzerland
| | | | | | | |
Collapse
|
19
|
Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002; 99:95-100. [PMID: 11756653 PMCID: PMC117520 DOI: 10.1073/pnas.012283399] [Citation(s) in RCA: 239] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2001] [Indexed: 12/11/2022] Open
Abstract
p53 can adopt two forms in vitro, a latent form that binds naked DNA poorly and an active form that binds DNA well. Conversion of the latent form to the active form is thought to occur by an allosteric mechanism induced by phosphorylation and acetylation. Despite the large differences in affinity produced by regulatory modifications in vitro, mutation of putative regulatory sites has not produced correspondingly large effects on transcription of p53 target genes in vivo. To determine whether genotoxic stress regulates DNA binding by p53 in vivo, we have performed quantitative chromatin immunoprecipitation (ChIP) assays on tumor and normal cell lines containing wild-type p53. ChIP recovers several hundredfold more p21 and MDM2 promoter DNA from p53 wild-type than p53-null cells, indicating that the assay is specific for p53. Genotoxic stress induces much smaller increases in chromatin precipitation, which are matched by changes in the p53 protein level. Thus, in the experimental systems tested, allosteric regulation of DNA binding is not a major level of regulation of p53 activity. The p53 target genes tested can be divided into a group showing high promoter occupancy in vivo (p21, MDM2, and PUMA) and a group giving substantially weaker or background p53 binding (bax, AIP1, and PIG3). Neither group shows selective recruitment of p53 to the promoter in cells undergoing apoptosis, indicating that the decision to undergo apoptosis or cell cycle arrest depends on other changes in the cell.
Collapse
Affiliation(s)
- M D Kaeser
- Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), 1066 Epalinges, Switzerland
| | | |
Collapse
|
20
|
Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001; 22:515-7. [PMID: 11238194 DOI: 10.1093/carcin/22.3.515] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Several reports have noted epidemiological differences in the prevalence or prognostic significance of p53 mutants with arginine (R) or proline (P) at the codon 72 polymorphism (R72/P72) in certain cancer types, but the biological significance of these variants is unclear. The ability of p53 mutants to interact with and inactivate the p53 homolog p73 was recently reported to depend on the conformational state of the p53 protein and the residue at codon 72. Since the conformation of p53 mutants may influence their ability to transdominantly inhibit wild-type p53, we tested whether there was a correlation between the amino acid at codon 72 and the transdominance of p53 alleles found in tumors. The transdominance test was performed using a simple yeast transcription assay, and the amino acid at codon 72 was determined by sequencing. A total of 100 p53 mutants were tested. Compared with the germline frequency (R:P = 427:297), an extreme bias in favor of the R72 allele was observed with recessive mutants (R:P = 50:7, P < 0.0002), whereas no selection for the R72 allele was seen with transdominant mutants (R:P = 23:20). p53 and p73 are known to transactivate overlapping sets of target genes. We interpret the R72 bias with recessive mutants as evidence that decreased activation of p53 target genes provides a selective growth advantage to tumor cells during the stage of tumorigenesis in which a wild-type and mutant p53 allele coexist. We suggest that transdominant p53 mutants achieve this by inactivation of the remaining wild-type p53 allele, whereas recessive p53 mutants achieve it through inactivation of p73.
Collapse
Affiliation(s)
- M Tada
- Division of Cancer-Related Genes, Institute for Genetic Medicine, Hokkaido University, N-15 W-7, Kita-Ku, Sapporo, 060-0815, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
We examined the frequency of p53 mutations in 38 oropharyngeal squamous cell carcinomas (SCC), using both a yeast functional assay and a conventional immunohistochemical staining method (IHC) to detect p53 mutations. We also explored the clinical importance of p53 mutations in oropharyngeal SCC. An accumulation of p53 protein was detected in 17 of the 38 (45%) tumors by IHC, whereas the yeast-based assay detected 6 additional p53 mutations, for a total of 23 tumors (61%) with p53 mutations. The cDNA sequencing analysis revealed that the 6 mutations undetected by IHC consisted of 3 frameshift, 1 nonsense and 2 missense mutations. Thus, the yeast functional assay was more sensitive than conventional IHC for detecting p53 mutations. Subsequently, the relationship between p53 mutations and the clinico-pathological parameters in oropharyngeal SCC was evaluated using the results of the functional assay. Mutation of p53 was not associated with the patient age, sex, tumor stage or degree of tumor cell differentiation. Interestingly, heavy drinking had a significant positive correlation with the p53 mutation, but heavy smoking did not, suggesting that prolonged exposure to alcohol is more related to p53 mutation in oropharyngeal SCC than to tobacco consumption. Radiation sensitivity was examined by comparing tumor size on magnetic resonance images before and after completion of therapy with 45 Gy radiation, in the 18 cases of T2 oropharyngeal SCC that were initially treated by radiotherapy. The results showed that tumors with wild-type p53 decreased in size significantly compared to those with mutant p53. In 33 patients treated with curative intent, the overall survival after the completion of therapy was better in patients with a wild-type p53 tumor than in patients with a mutant p53 tumor. We conclude that p53 mutation is associated with radiation resistance and a decreased probability of survival in oropharyngeal SCC.
Collapse
Affiliation(s)
- A Obata
- Department of Otolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Previously a low frequency of p53 mutations was detected in nasopharyngeal carcinoma (NPC) using molecular techniques to screen for mutations, yet immunohistochemical staining revealed a high frequency of p53 aberrant proteins. These findings might be attributed to the occurrence of p53 mutations outside the common hot spots and/or the inactivation of the protein through interactions with cellular or viral proteins. Using a previously established simple and sensitive p53 yeast functional assay, we blindly screened 25 nasopharyngeal biopsies for p53 mutations from exons 4 to 11. p53 was mutated in 27.3% of NPC specimens and in 0% of the nasopharyngeal biopsies from patients with non-malignant diseases. Two p53 mutations were detected in exon 7 and two were detected in exon 8. Interestingly, the exon 8 mutations observed in NPC lie in codons which appear to be hot spots for mutations in other head and neck cancers.
Collapse
Affiliation(s)
- M L Lung
- Department of Biology, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon.
| | | | | | | | | | | | | |
Collapse
|
23
|
Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998; 58:1793-7. [PMID: 9581814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Recent studies suggest that a balance may exist between the cell cycle arrest and apoptosis-inducing functions of the p53 tumor suppressor gene. Adenoviral p21 transduction attenuates apoptosis, whereas deletion of the p21 gene promotes it, and p21-null xenografts respond better than isogenic p21-wild type tumors to irradiation. Hence, the role of p53 in dictating the clinical response to radiotherapy and chemotherapy may be more complex than previously thought. We have analyzed survival and radiation response (regrowth-free period) of 42 patients with glioblastomas whose p53 status was determined by a sensitive yeast functional assay. Multivariate analysis revealed that p53 mutation is associated with longer survival (P < 0.02). Among 36 radiation-treated patients, the regrowth-free period after treatment was significantly longer for tumors with p53 mutations (P < 0.0001), and p53 mutation was the sole independent factor predictive of radiotherapeutic response (P < 0.01). Survival time after regrowth was independent of p53 status, suggesting that the difference in survival was related to the treatment rather than to the intrinsic aggressiveness of the tumor. Thus, in this Northern Japanese population, p53 mutation is a marker for better radiation response in glioblastomas, and this results in significantly longer survival.
Collapse
Affiliation(s)
- M Tada
- Laboratory for Molecular Brain Research, Hokkaido University School of Medicine, Sapporo, Japan.
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Monitoring the transduction efficiency is of paramount importance in gene therapy. To monitor adenovirus-mediated wild-type p53 gene transfer, we have used a quantitative assay which tests the ability of human p53 to activate transcription in yeast. Selective amplification of cellular and viral p53 transcripts followed by quantitative assessment of mutant p53 content with the assay permits measurement of the wild-type p53 transduction efficiency into SF-188, U251MG and HUG31 glioblastoma cells. One reverse transcription primer tracks the wild-type/mutant ratio of endogenous p53 mRNA (P2), and the other the wild-type/mutant ratio of both endogenous and exogenous p53 mRNA (P1). Following infection of cell lines homozygous for mutant p53, the apparent transduction efficiency calculated (tau 0 = [P1-P2]/[1 + P2]) correlated with the level of p21 expression. Transduction efficiency in heterozygous wild-type/mutant HUG31 cells increased linearly with multiplicity of infection (MOI) for tau 0 values between 0.5 and 5.9, and admixture of normal cell-derived RNA produced only a modest reduction in tau 0 value, in keeping with theoretical predictions. These results suggest that the yeast p53 functional assay may be a useful tool for monitoring p53 gene therapy.
Collapse
Affiliation(s)
- M Tada
- Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | |
Collapse
|
25
|
Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol 1998; 95:291-6. [PMID: 9542595 DOI: 10.1007/s004010050800] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
While it is established that p53 mutation plays a critical role in the carcinogenesis of astrocytic brain tumors, its role remains to be clarified for other types of tumors in the central nervous system (CNS). Using a yeast-based assay which tests the ability of human p53 to activate transcription, we analyzed p53 mutations in 85 non-astrocytic CNS tumors, including 4 benign neuronal tumors (3 central neurocytomas and 1 pineocytoma), 12 primitive neuroectodermal tumors, 14 germ cell tumors (7 germinomas, 7 non-germinomatous tumors), 4 craniopharyngiomas, 14 ependymomas, 22 schwannomas, 10 primary brain lymphomas in immunocompetent patients, and 5 bone tumors of the skull. The only tumors found to contain p53 mutations were 3 malignant lymphomas. The presence of mutations in these cases was confirmed by DNA sequencing. Given the high accuracy and sensitivity of the yeast assay and previous negative results using conventional techniques, this indicates that p53 mutation is a rare event in non-astrocytic CNS tumor types examined here.
Collapse
Affiliation(s)
- M Nozaki
- Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan
| | | | | | | | | | | |
Collapse
|
26
|
Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997; 379:211-8. [PMID: 9357550 DOI: 10.1016/s0027-5107(97)00149-8] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We have used a yeast p53 functional assay to study induction of mutations in the p53 tumor suppressor gene by nitric oxide and cytosine methylation. The yeast assay identifies only biologically important p53 mutations. p53 cDNA was treated with the nitric oxide donor sydnonimine, PCR-amplified and transfected into yeast. Sydnonimine produced a significant, dose-dependent increase in C:G-->A:T transversions. Many important p53 mutational hotspots are postulated to arise by deamination of methylCpG in tumors. We therefore examined nitric oxide induction of mutations in p53 cDNA methylated by PCR-mediated substitution of 5-methylcytosine for cytosine or by treatment with the SssI CpG methylase. Both methylation procedures increased the baseline mutation rate, and nitric oxide treatment produced a further increase in mutation yield. Sequence analysis showed that methylation alone led to C:G-->T:A transitions, whereas nitric oxide treatment simply produced more C:G-->A:T transversions. Thus the most important factor in C:G-->T:A transition at CpG sites identified in this experimental system is cytosine methylation, consistent with spontaneous conversion of 5-methylcytosine to thymine by deamination.
Collapse
Affiliation(s)
- J Murata
- Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan
| | | | | | | | | | | |
Collapse
|
27
|
Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses. Mol Carcinog 1997. [DOI: 10.1002/(sici)1098-2744(199703)18:3<171::aid-mc6>3.0.co;2-i] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
28
|
Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol Carcinog 1997; 18:171-6. [PMID: 9115587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We previously reported clonal expansion of p53 mutations in malignant astrocytic tumors detected with a yeast p53 functional assay that measures mutant p53 alleles quantitatively and loss of p53 transcriptional competence qualitatively (Tada et al., Int J Cancer 67:447-450, 1996). This method selectively detects inactivating mutations and is relatively insensitive to contamination of tumor samples with normal tissue. To determine whether the mutation frequency and spectrum detected in this way differ from those seen with conventional techniques, 54 malignant astrocytomas were tested with the yeast assay, and the abnormalities detected were characterized by DNA sequencing. Inactivating p53 mutations were found in 67% of anaplastic astrocytomas and 41% of glioblastomas. Overall, mutations were found in 48% of tumors, compared with only 29% in previous studies (P < 0.005), a difference that probably reflects the greater sensitivity of the yeast assay than of conventional techniques. The frequency of mutations in anaplastic astrocytomas (in our study plus published studies) was significantly higher than in glioblastomas (39% vs 29%; P < 0.05). This suggests that acquisition of p53 mutations is not rate limiting for progression to glioblastoma and that many glioblastomas develop by p53-independent pathways. Sequencing of mutant p53 cDNAs rescued from yeast showed that the mutation spectrum for functionally inactive mutants was nearly identical to the spectra from previous studies on structural mutants, indicating that transcriptional activity is the critical biological target of p53 mutation in malignant astrocytomas.
Collapse
Affiliation(s)
- M Tada
- Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 1996; 67:447-50. [PMID: 8707423 DOI: 10.1002/(sici)1097-0215(19960729)67:3<447::aid-ijc22>3.0.co;2-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Mutation of the p53 gene is found in about one third of astrocytic brain tumors, and expansion of tumor cell clones containing mutant p53 has been implicated in astrocytic tumor progression. However, admixture of normal cells in astrocytic tumor specimens limits the power of traditional studies of tumor cell clonality. To address this problem we have employed a yeast p53 functional assay that scores the content of mutant p53 alleles in tumors and cell lines quantitatively. We have analyzed 17 cases where matching tumor material and derived cell lines were available. The yeast assay gave > 20% red (i.e., mutant p53-containing) yeast colonies in 7 out of 17 cases. One case had no mutations in the primary tumor but gave 76% red colonies in a recurrence, clearly demonstrating tumor overgrowth by a mutant clone. During early passages of cultured tumor cells, mutant p53 content increased rapidly with passage due to outgrowth of mutant clones from a heterogeneous starting population. In addition, de novo p53 mutations appeared during culture in 2 cases. This indicates that there is stronger selective pressure for mutation during the establishment of cell lines in vitro than during tumor growth in vivo. Our results demonstrate the utility of the p53 functional assay for studies of clonality and support the hypothesis of clonal progression of brain tumors in vivo.
Collapse
Affiliation(s)
- M Tada
- Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The human nuclear antigen p68 cross reacts with a monoclonal antibody to SV40 large-T antigen. Its deduced amino acid sequence contains short motifs which place it in a large superfamily of proteins of known or putative helicase activity. Recently, a p68 subfamily (DEAD box proteins) which share more extensive regions of homology has been identified in mouse, Drosophila, Saccharomyces cerevisiae and Escherichia coli. These proteins are involved in translation, ribosome assembly, mitochondrial splicing, spermatogenesis and embryogenesis. We show here that immunopurified human p68 has RNA dependent ATPase activity. In addition, we show that the protein undergoes dramatic changes in cellular location during the cell cycle.
Collapse
Affiliation(s)
- R D Iggo
- Molecular Immunochemistry Laboratory, ICRF, South Mimms, Herts, UK
| | | |
Collapse
|
31
|
Affiliation(s)
- S E Mole
- Imperial Cancer Research Fund, Clare Hall Laboratories, Herts, UK
| | | | | |
Collapse
|